The Effect of Citrasate Dialysate on Heparin Dose in Hemodialysis
Launched by UNIVERSITY OF CALGARY · Nov 7, 2011
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
The investigators will perform a randomized, double-blind, two-period crossover trial in chronic HD patients to compare the effect of citrasate dialysate (CD) and usual acetic-acid based dialysate (AD) on the cumulative intradialytic heparin dose. There is a four week run in phase followed by two weeks of intervention AD or CD followed by the remaining AD or CD intervention.
The primary outcome is change in intradialytic heparin dose achieved with citrasate compared with acetate dialysate. Secondary outcomes are the effect of CD compared with AD on systemic anticoagulation, bleeding time a...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • chronic stable HD patients ≥ 18 years
- • on HD at least three times per week for at least 3 months
- Exclusion Criteria:
- • contraindication to heparin
- • currently using heparin-free HD
- • known clotting disorder
- • on warfarin therapy
- • dialyzing with a dysfunctional central venous catheter (blood flow rates consistently less than 300mL/min and/or frequent use of thrombolytic)
- • history of vascular access dysfunction
- • planned vascular access conversion or procedure during the study period
- • use of high calcium dialysate
- • active medical issue requiring hospitalization
- • planned kidney transplant during the study period
- • planned conversion of dialysis modality (peritoneal dialysis, nocturnal dialysis) during the study period
- • unable to provide informed consent
About University Of Calgary
The University of Calgary is a leading research institution dedicated to advancing health and science through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university's clinical research initiatives aim to address pressing health challenges and improve patient outcomes. The institution fosters a robust environment for academic inquiry, leveraging state-of-the-art facilities and a diverse network of experts in various fields. Committed to ethical research practices and community engagement, the University of Calgary strives to translate scientific discoveries into tangible benefits for society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Calgary, Alberta, Canada
Patients applied
Trial Officials
Jennifer M MacRae, MD FRCPC
Study Director
University of Calgary
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials